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A B S T R A C T
Of the 200 Clostridium spp. known to exist, approximately 30 have been associated with human disease.
Commonly found in soil, marine sediment and mammalian intestinal tracts, these gram-positive bacilli
are known to cause infections ranging from cellulitis to septicemia. Isolates that are identified by clinical
microbiology laboratories include Clostridium perfrigens species in 20–40% of cases. However, when
Clostridium sporogenes is identified, is rarely considered to be pathogenic. We present a case of Clostridium
sporogenes bacteremia secondary to lower limb cellulitis and osteomyelitis in an immunocompetent
patient.
© 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Case presentation
A 66-year-old woman with a history of morbid obesity,
hypertension, hyperlipidemia, non-insulin dependent diabetes
mellitus and coronary artery disease was admitted to our hospital
for sepsis secondary to lower extremity ulceration and osteomye-
litis.
Two weeks before this admission, the patient contacted family
members for assistance and was found to be immobilized in the
collapsed floor of her mobile home and without access to hydration
for long time. Despite the squalid living condition of her home, the
patient initially refused outside assistance before requesting
medical attention. She was then transported by emergency
medical services to our emergency department.
On examination, the patient appeared to be anxious. The
temperature was 99.8o F, pulse 109 beats per minute, blood
pressure 128/60 mm Hg, and respiratory rate 18 breaths per
minute. Skin examination showed multiple necrotic ulcers with
brown discharge located in her bilateral lower extremities, left heel
and sacral decubitus area. Electrocardiograph showed atrial
fibrillation with rapid ventricular response. Computed tomography
of the thorax and abdomen yielded no acute abnormalities.
On admission to the surgical intensive care unit, vancomycin
and piperacillin-tazobactam were administered intravenously for
empiric coverage of common pathogens implicated in sepsis and
clinical gas gangrene. Complete blood count was significant for a
white cell count of 23.6k per mm3, hemoglobin 9.7 g/dL, and
platelet count of 601k per mm3. Comprehensive metabolic panel
was significant for sodium 128 mEq/L, bicarbonate 18 mEq/L, urea
nitrogen 46 mg/dL and creatinine 2.03 mg/dL. Lactic acid was
2.76 mmol/L. Cultures of urine and blood were send to the clinical
microbiology laboratory and orthopedic and infectious disease
services were consulted.
Blood cultures grew Clostridium sporogenes in two out of two
bottles that was obtained from one site (one aerobic and one
anaerobic bottle) and urine cultures grew Enterococcus spp. (with
colony forming units count more than 200,000). Antimicrobials
were switched to daptomycin, ertapenem and clindamycin. Repeat
blood cultures were negative after 5 days of incubation. Clinical gas
gangrene with severe destruction to the subcutaneous tissue was
documented affecting the whole planter surface of the left foot as
well as parts of the right foot. General surgery was consulted, who
recommended below knee amputation of the left leg and right foot
disarticulation. Patient refused the amputations. Despite the
treatment with antimicrobial agents, patient clinical conditions
continued to deteriorate. At that time, the patient refused all
medical management, was placed on comfort measures and
expired shortly thereafter.
Discussion
Clostridium sporogenes is an anaerobic, gram-positive bacillus
that comprises a part of the normal intestinal flora. First
described in 1908, C. sporogenes has been isolated from the
gastrointestinal tracts of both healthy individuals as well as those
with chronic colitis [1]. Sporadic infections manifest in a wide
variety of pathologies, including septic arthritis, empyema, and gas
gangrene [2–5].
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Clostridial species represent a widely divergent group from
strict anaerobes to aerotolerant species, and from pathogens
producing virulent toxins to harmless saprophytes [6]. Clostridium
sp. may be involved in a wide variety of infections and is a common
cause of enteritis and enterotoxaemia humans [7]. The causes of
these diseases are usually endogenous (e.g. brain abscess,
pneumonia, intra-abdominal abscess, cholecystitis, bacteremia)
and arise from the microflora of the host. However, others may be
exogenous, such as food poisoning, pseudomembranous colitis,
tetanus, botulism and gas gangrene [8]. One review found that
about two thirds of the patients have been older than 65 years [9].
The most common underlying conditions in fore-mentioned
review were diabetes, malignancy and neutropenia.
Of the 23 reported cases of Clostridium sporogenes, 16 involved
bacteremia, 1 involved a pyogenic liver abscess, 2 involved
empyema, 1 involved septic arthritis, and 2 involved septicemia
[2–4,10,11]. Gorbach et al. reviewed reports of 87 clostridial soft
tissue infections and found C. sporogenes to be implicated in only 3
cases [12]. In 130 reported cases of gas gangrene, C. sporogenes was
identified in only one case [13]. In a review of 136 cases of
clostridial bacteremia in cancer patients by Bodey et al., 12 cases
were identified as C. sporogenes [14].
Mortality rates associated with clostridial bacteremia have
been reported to be as high as 34% and 55% for monomicrobial and
polymicrobial infections, respectively [14]. Thus, prompt initiation
of appropriate antimicrobial therapy is critical in reducing the
mortality of clostridial bacteremia/septicemia. This is critical when
there are associated underlying conditions including alcoholism,
intra-abdominal surgery and necrosis of small and/or large bowel.
While the exact underlying pathogenesis of C. sporogenes remains
unclear but is suspected to involve the production of a
hemorrhagic toxin and proteinases [15–17]. In our case, the
diagnosis was made through blood cultures obtained prior to
empiric treatment with intravenous piperacillin-tazobactam and
vancomycin.
The success of the treatment of established gas gangrene in
clinical practice has depended largely upon early diagnosis and
prompt surgical intervention as means to control the source of
infection. Urgent, thorough surgical debridement is mandatory to
improve survival, preserve limbs, and prevent complications [12].
Several types of antibiotics, including penicillin, clindamycin,
rifampin, metronidazole, chloramphenicol, tetracycline, and
erythromycin have been shown to be effective in vitro or in
animal studies. Historically in humans, penicillin G has been
recommended in doses of between 10 and 24 million units per day.
Currently, a combination of penicillin and clindamycin is widely
used for treating clostridial gas gangrene. The rationale for using
penicillin in combination with clindamycin is that some strains of
Clostridium are resistant to clindamycin but susceptible to
penicillin. Clindamycin is thought to be the superior drug for
reducing toxin formation [18].
Other, non-clostridial bacteria are frequently found in gas
gangrene tissue cultures, so treatment that is active against Gram-
positive (e.g. penicillin or cephalosporin), Gram-negative (e.g.
amino- glycoside, cephalosporin, or ciprofloxacin), and anaerobic
organ- isms (e.g. clindamycin or metronidazole) should be
combined in the antibiotic therapy until the results of bacterio-
logical culture are known [18].
Use of multiple drugs active against anaerobes is not necessary
and puts the patients at risk for additional drug toxicities. No data
or guidelines support the use of two anti-anaerobic drugs in
clinical practice. In some cases, double anaerobic coverage is
preferred by many clinicians, for example metronidazole can be
added to another agent with anaerobic activity when being used to
treat clostridium difficile infection. Another situation is clindamycin
which can be added to another agent with anaerobic activity when
being used for the treatment of necrotizing fasciitis [19]. Even in
the case of single agents that cover all 3 categories of bacteria, (eg,
broad-spectrum penicillins) Dual antibiotic therapy is recom-
mended for all necrotizing soft-tissue infections given observed
synergism in animal models [20].
First line treatment of confirmed C. sporogenes is traditionally
with penicillins. In a study performed by Roberts et al., C.
sporogenes was found to have 100% susceptibility to penicillins
(amoxicillin-clavulanate and piperacillin-tazobactam), cephalo-
sporins (cefoxitin, cefotetan, and ceftriaxone), clindamycin,
carbapenems (imipenem and meropenem) as well as metronida-
zole [21] Blood cultures obtained after the initiation of antimicro-
bial treatment was negative for C. sporogenes after 5 days of
incubation, nevertheless due to high suspicion for being a source of
infection, amputation of the patient’s foot was recommended. This
recommendation, along with any form of medical treatment, was
refused by the patient, who expired within a few days of treatment
cessation.
Conclusion
Clostridium sporogenes is a rare clinical pathogen and thus its
discovery as the bacteremic agent in an immunocompetent patient
made this case an unusual one. As with any patient suspected of
being septic, obtaining cultures and routine susceptibility tests and
initiating antimicrobial therapy in a timely manner are critical for
obtaining an optimal outcome. However, without a rapid
diagnostic test for Clostridium spp., prompt diagnosis is often
difficult resulting in broad empiric therapy. Fortunately, Clostridi-
um species remain susceptible to many antibiotics used in the
treatment of bacteremia, osteomyelitis and sepsis but may not
prevent progression to death.
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